• Kailera Therapeutics named Nur Nicholson chief technology officer, effective Aug. 31, 2026.
• Role centers on scaling manufacturing and supply capabilities as ribupatide injection moves through global Phase 3 trials.
• Phase 3 program for ribupatide oral is slated to start in the first half of next year.
• Nicholson was chief technical operations officer at Apellis Pharmaceuticals, leading technical operations through its shift to commercial scale.
• Earlier roles included global supply chain leadership at Galderma, plus operations posts at Alcon Pharmaceuticals, a Novartis company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807279) on August 11, 2026, and is solely responsible for the information contained therein.